Personnalized treatments by High Intensity Focused Ultrasound – SMART-HIFU

The company EDAP-TMS France and the laboratory LabTAU, INSERM unit 1032, decided to create a joint laboratory LabCom to strengthen and transform several decades of collaboration engaged in the surgical application of therapeutic ultrasound.
The main axis of research concerns the development of transversal digital technologies for the modeling of ultrasound treatments, the prediction and control of their effectiveness within the framework of personalized therapeutic protocols for patients suffering respectively from urological pathologies (benign hypertrophy and prostate cancer) and gynecological (deep rectal endometriosis).
This work is based on the use of in silico methods developed by LabTAU and grouped under the aegis of the “Ablasim” platform and the Focal One® robotic medical device introduced to the European market in 2013 by the company EDAP-TMS France and whose next generations are currently being developed. This medical device is today indicated for the treatment of prostate cancer (in Europe) and prostate tissue (in the United States). The treatment of benign prostatic hypertrophy and deep rectal endometriosis in gynecology are two new indications currently undergoing clinical validation and which will expand the field of indications for the device in the coming years.
The collaborative dynamic created thanks to this LabCom will make it possible to accelerate the transfer of innovative digital technologies for planning, guiding and controlling the improvement of the therapeutic performance of the medical device. A major innovation would be the integration of artificial intelligence at the heart of the therapeutic process to help the surgeon define the treatment plan by predicting the thermal dose deposited and the delivery methods (focusing strategy, mode of action of ultrasound).